On this page
SOS2
SOS Ras/Rho guanine nucleotide exchange factor 2
SOS2 encodes a guanine-nucleotide exchange factor for RAS GTPases, a close paralogue of SOS1, acting in the RAS/MAPK pathway. Germline activating SOS2 variants cause a rare autosomal dominant Noonan syndrome subtype, often with prominent ectodermal features and short stature, overlapping phenotypically with SOS1-related disease.
SOS2 is located on the long (q) arm of chromosome 14, at band 14q21.3. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 14 in the library →Available at Jeen Health
Clinical tests that include this
Overview
SOS2 (SOS Ras/Rho guanine nucleotide exchange factor 2) encodes a protein belonging to a family of enzymes that control how cells respond to external signals and coordinate growth. The SOS2 protein acts as a molecular switch operator, activating RAS proteins that relay messages from the cell surface to the nucleus. These signalling cascades influence cell division, differentiation, and survival across many tissue types during development and throughout life.
When SOS2 functions normally, it helps ensure that cells grow and divide at appropriate rates and times. Pathogenic variants in this gene can cause the RAS pathway to become overactive, resulting in a group of related developmental disorders collectively known as RASopathies. These conditions share overlapping features affecting growth, cardiac structure, skeletal development, skin pigmentation, and cognitive function. SOS2-related disorders follow an autosomal dominant inheritance pattern, meaning a single altered copy of the gene is sufficient to cause the condition.
What the gene does
The SOS2 protein functions as a guanine nucleotide exchange factor, catalysing the exchange of GDP for GTP on RAS proteins. This exchange activates RAS, enabling it to interact with downstream effectors that propagate signals controlling cell proliferation, differentiation, and survival. SOS2 operates primarily in response to receptor tyrosine kinase activation at the cell membrane, where growth factors and other extracellular signals trigger its recruitment and activation.
Unlike some exchange factors that act constitutively, SOS2 activity is tightly regulated through multiple mechanisms. The protein contains autoinhibitory regions that restrict its catalytic function until appropriate upstream signals arrive. Binding to adaptor proteins and membrane lipids relieves this inhibition, allowing SOS2 to engage RAS proteins efficiently. The exchange factor also exhibits positive feedback properties: activated RAS can bind to regulatory sites on SOS2, further enhancing its catalytic output and amplifying the signal.
SOS2 shows some functional overlap with its close relative SOS1, though the two proteins are not entirely redundant. Expression patterns differ across tissues and developmental stages, and biochemical studies suggest subtle differences in substrate preference and regulatory responsiveness. The balance of SOS1 and SOS2 activity appears important for fine-tuning RAS pathway output in different cellular contexts, particularly during embryonic development when precise control of cell fate decisions is essential.
Video: Genetics 101
Chromosome location
The SOS2 gene resides on chromosome 14 at cytogenetic band 14q21.3, positioned in the long arm of the chromosome. This genomic region contains multiple genes involved in cellular signalling and developmental processes. The chromosomal location of SOS2 has remained stable throughout mammalian evolution, suggesting functional constraints on its genomic neighbourhood. The gene comprises 41 exons spanning approximately 120 kb of genomic DNA.
Protein structure
The SOS2 protein comprises 1332 amino acids organised into distinct functional modules that work together to regulate nucleotide exchange activity. The N-terminal region contains a DH domain (amino acids 198-388) followed by a PH domain (amino acids 442-546), which together mediate interactions with membrane lipids and contribute to subcellular localisation. These domains help position SOS2 at the plasma membrane where RAS proteins reside.
The catalytic core consists of two consecutive modules: an N-terminal Ras-GEF domain (amino acids 595-739) and a larger Ras-GEF domain (amino acids 778-1017). These regions form the active site responsible for catalysing GDP release and GTP binding on RAS substrates. The architecture of this catalytic machinery allows SOS2 to engage RAS proteins and stabilise the nucleotide-free intermediate state necessary for efficient exchange.
The C-terminal portion of SOS2 contains extensive disordered regions (amino acids 1018-1061, 1076-1096, and 1142-1332). Intrinsically disordered segments often serve regulatory functions, providing flexible linkers between structured domains or housing modification sites and protein interaction motifs. These regions likely contribute to the dynamic regulation of SOS2 activity and its integration into larger signalling complexes.
Key variants
Pathogenic variants in SOS2 typically result in gain-of-function effects that increase RAS pathway activation beyond normal physiological levels. Most disease-causing changes are missense variants that disrupt autoinhibitory interactions or stabilise the active conformation of the exchange factor, leading to sustained signalling output. The variant spectrum shows some clustering in functionally critical regions, particularly those involved in regulating catalytic activity.
The majority of SOS2 variants associated with developmental conditions arise de novo, appearing for the first time in affected individuals rather than being inherited from parents. This pattern reflects the strong selective pressure against germline transmission of variants that significantly perturb RAS signalling during early development. Somatic variants in SOS2 have also been identified in certain cancers, though the gene is not among the most frequently mutated oncogenes in malignancy.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1127C>G | p.Thr376Ser | Pathogenic | ★★☆☆ | Noonan syndrome 9 |
c.791C>A | p.Thr264Lys | Pathogenic/Likely pathogenic | ★★☆☆ | Noonan syndrome 9 |
c.791C>G | p.Thr264Arg | Pathogenic | ★★☆☆ | Noonan syndrome 9 |
c.800T>C | p.Met267Thr | Pathogenic | ★★☆☆ | Noonan syndrome 9 |
c.800T>G | p.Met267Arg | Pathogenic/Likely pathogenic | ★★☆☆ | SOS2-related disorder |
c.1126A>T | p.Thr376Ser | Pathogenic | ★☆☆☆ | Noonan syndrome 9 |
c.1291G>A | p.Glu431Lys | Pathogenic | ★☆☆☆ | Noonan syndrome 9 |
c.800T>A | p.Met267Lys | Likely pathogenic | ★★★☆ | Noonan syndrome 9 |
c.1127C>T | p.Thr376Ile | Likely pathogenic | ★☆☆☆ | Noonan syndrome 9 |
c.26A>G | p.Glu9Gly | Likely pathogenic | ★☆☆☆ | Male infertility due to gonadal dysgenesis or sperm disorder |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in SOS2 cause a spectrum of developmental conditions characterised by distinctive facial features, growth abnormalities, cardiac defects, and variable cognitive impairment. The most commonly recognised SOS2-related disorder is Noonan syndrome, which presents with short stature, chest deformity, webbed neck, bleeding tendency, and congenital heart disease affecting valve structure or the cardiac muscle itself. Cardiac defects affect the majority of individuals with RASopathies, with hypertrophic cardiomyopathy occurring in approximately 20-30% of individuals with SOS1 or SOS2 variants based on available RASopathy cohort data, though SOS2-specific frequencies remain less well-defined due to smaller case series.
The phenotypic presentation of SOS2-related conditions overlaps substantially with other RASopathies caused by variants in genes such as PTPN11, RAF1, and SOS1. Clinical features may include widely spaced eyes, low-set ears, feeding difficulties in infancy, delayed puberty, and lymphatic abnormalities. Some individuals develop skin pigmentation changes including café-au-lait spots or lentigines (multiple small dark spots). Intellectual disability occurs in approximately 20-30% of cases based on studies across RASopathy cohorts, ranging from mild learning difficulties to more significant cognitive impairment requiring educational support. These frequency estimates derive from broader RASopathy literature, as SOS2-specific cohorts remain relatively limited in size.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic SOS2 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
SOS2 holds green (high confidence) status across multiple NHS Genomic Medicine Service gene panels, reflecting its established role in diagnosing developmental disorders within the UK healthcare system (NHS Genomic Medicine Service PanelApp, accessed January 2025). The gene appears on the RASopathies panel, which guides testing for conditions caused by dysregulated RAS-MAPK signalling. It is also included on panels for intellectual disability, monogenic short stature, and paediatric or syndromic cardiomyopathy, acknowledging the varied clinical presentations that can prompt genetic investigation.
Additional panel memberships include foetal anomalies, foetal hydrops, primary lymphoedema, and pigmentary skin disorders, reflecting the range of features that may be detected prenatally or in early life. The gene's presence on the DDG2P (Developmental Disorders Genotype-to-Phenotype) database further supports its use in diagnostic evaluation of children with unexplained developmental delay or multiple congenital anomalies. These designations facilitate access to NHS genetic testing for individuals whose clinical presentation raises suspicion of a SOS2-related condition. Clinical teams should verify current panel status as designations may be updated over time.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
For individuals diagnosed with SOS2-related conditions, general health recommendations focus on managing specific manifestations rather than modifying the underlying genetic variant. Regular cardiac monitoring is important given the risk of hypertrophic cardiomyopathy or valvular abnormalities, with clinical guidelines often recommending periodic echocardiography and electrocardiography. Physical activity recommendations may be tailored based on cardiac findings, with some individuals advised to avoid particularly strenuous exercise if significant structural heart disease is present.
Growth monitoring throughout childhood allows clinicians to identify whether growth hormone therapy might benefit individuals with significant short stature, though response to treatment can vary. Nutritional support during infancy may help address feeding difficulties common in RASopathies. Educational planning that accounts for any learning difficulties or developmental delays can optimise outcomes for children with cognitive impairment. These lifestyle and management considerations should be discussed with a multidisciplinary healthcare team familiar with RASopathies.
Supplement considerations
There is no conclusive evidence that dietary supplements can prevent or ameliorate the features of SOS2-related conditions. The developmental abnormalities result from altered cellular signalling during embryonic and postnatal growth, and nutritional interventions have not been shown to modify these fundamental processes. Some families inquire about antioxidants or other supplements based on general interest in supporting cellular health, but no rigorous clinical trials have demonstrated benefit for core RASopathy features.
Individuals considering any supplement regimen should discuss it with their healthcare provider, particularly since some supplements may interact with cardiac medications or other treatments used to manage specific manifestations of the condition. A balanced diet appropriate for age and growth needs remains the cornerstone of nutritional support, with supplementation reserved for documented deficiencies identified through clinical assessment.
Frequently asked questions
What is the difference between SOS1 and SOS2?
SOS1 and SOS2 are closely related genes encoding similar guanine nucleotide exchange factors for RAS proteins. Both can cause Noonan syndrome when altered, though they show some differences in tissue expression patterns and clinical presentation. The proteins share substantial sequence similarity but are not entirely interchangeable in all developmental contexts.
Are SOS2 variants always inherited from a parent?
Most pathogenic SOS2 variants occur de novo, meaning they appear for the first time in the affected individual rather than being inherited. However, because the condition follows autosomal dominant inheritance, an affected individual has a 50% chance of passing the variant to each of their children.
Can SOS2 variants be detected through carrier screening?
Standard carrier screening panels typically focus on recessive conditions where two variant copies are needed to cause disease. Because SOS2-related conditions are autosomal dominant, a single variant copy causes features, so traditional carrier screening is less applicable. Diagnostic testing is usually performed when clinical features raise suspicion of a RASopathy.
What heart problems are associated with SOS2 variants?
Cardiac manifestations of SOS2-related conditions include hypertrophic cardiomyopathy (thickening of the heart muscle), pulmonary valve stenosis (narrowing), and other structural heart defects. Regular cardiac monitoring with echocardiography is typically recommended to detect and manage these complications.
Is there genetic testing available on the NHS for SOS2?
Yes, SOS2 is included on multiple NHS Genomic Medicine Service gene panels with green (high confidence) status. Testing may be accessed through clinical genetics services when an individual presents with features consistent with a RASopathy, such as distinctive facial characteristics, short stature, or congenital heart disease.